The Tuklas Lunas program of the Department of Science and Technology (DOST) remains in full swing as one of its projects is set for completion soon.
The clinical trial, which costs nearly P12 million and is being implemented by Pharmalytics Corp., is funded by the DOST through its Philippine Council for Health Research and Development (PCHRD).
The randomized, double-blind, placebo-controlled study being conducted in Cavite, aims to determine the efficacy and safety of an herbal capsule when taken orally by adults with dengue fever but showing no warning signs.
Dengue is a mosquito-borne infection which incidence has been steadily increasing in tropical countries, like in the Philippines, where it is considered as one of the top health problems.
Once proven safe and effective, the herbal capsule will be the first definitive treatment for dengue. It could pave the way for use in cases showing warning signs and even in severe types.
On the economic side, farmers can benefit from cultivating any of the three medicinal plants, the increased demand for which may come from local pharmaceutical companies that could manufacture the treatment for domestic and even overseas markets.
Allyster A. Endozo, S&T Media Services